Neovacs Valuation Multiples

Neovacs is valued at $8K as of November 2026, a 2.2x revenue multiple. In the last fiscal year, Neovacs revenue was $355K and Neovacs EBITDA was ($6M).

Neovacs Overview

About Neovacs

Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.


Founded

1993

HQ

France

Employees

16

Website

neovacs.fr

Financials (Last FY)

Revenue: $355K
EBITDA: ($6M)

EV

$772K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Neovacs Financials

Neovacs reported last fiscal year revenue of $355K and negative EBITDA of ($6M).

In the same fiscal year, Neovacs generated $68K in gross profit, ($6M) in EBITDA losses, and had net loss of ($5M).


Neovacs P&L

In the most recent fiscal year, Neovacs reported revenue of $355K and EBITDA of ($6M).

Neovacs is unprofitable as of last fiscal year, with gross margin of 19%, EBITDA margin of (1595%), and net margin of (1514%).

See analyst estimates for Neovacs
Last FY202320242025202620272028
Revenue$355K$621K$426K$355K
Gross Profit$68K$35K$49K$68K
Gross Margin19%6%12%19%
EBITDA($6M)($7M)($33M)($6M)
EBITDA Margin(1595%)(1134%)(7660%)(1595%)
EBIT Margin(1675%)(2305%)(3732%)(1675%)
Net Profit($5M)($10M)($38M)($5M)
Net Margin(1514%)(1637%)(8985%)(1514%)
Net Debt($38K)---

Financial data powered by Morningstar, Inc.

Neovacs Stock Performance

Neovacs has current market cap of $8K, and enterprise value of $772K.

Market Cap Evolution


Neovacs' stock price is $0.05.

Neovacs share price decreased by 51.3% in the last 30 days, and by 57.2% in the last year.

Neovacs has an EPS (earnings per share) of $-33.65.

See more trading valuation data for Neovacs
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$772K$8K-20.1%-51.3%-88.8%-57.2%$-33.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Neovacs Valuation Multiples

Neovacs trades at 2.2x EV/Revenue multiple, and (0.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Neovacs

Neovacs Financial Valuation Multiples

As of November 20, 2026, Neovacs has market cap of $8K and EV of $772K.

Neovacs has a P/E ratio of (0.0x).

Last FY202320242025202620272028
EV/Revenue2.2x1.2x1.8x2.2x
EV/EBITDA(0.1x)(0.1x)(0.0x)(0.1x)
EV/EBIT(0.1x)(0.1x)(0.0x)(0.1x)
EV/Gross Profit11.4x22.0x15.7x11.4x
P/E(0.0x)(0.0x)(0.0x)(0.0x)
EV/FCF(0.3x)(0.3x)(0.1x)(0.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Neovacs Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Neovacs Margins & Growth Rates

In the most recent fiscal year, Neovacs reported gross margin of 19%, EBITDA margin of (1595%), and net margin of (1514%).

See estimated margins and future growth rates for Neovacs

Neovacs Margins

Last FY20242025202720282029
Gross Margin19%12%19%
EBITDA Margin(1595%)(7660%)(1595%)
EBIT Margin(1675%)(3732%)(1675%)
Net Margin(1514%)(8985%)(1514%)
FCF Margin(842%)(1301%)(842%)

Neovacs Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(31%)(17%)
Gross Profit Growth41%37%
EBITDA Growth363%(83%)
EBIT Growth11%(63%)
Net Profit Growth276%(86%)
FCF Growth125%(46%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Neovacs Operational KPIs

Neovacs' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

Access forward-looking KPIs for Neovacs
Last FY202320242025202620272028
Revenue per Employee$0.0M---
Opex per Employee$0.4M---
Opex to Revenue1778%1394%1948%1778%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Novaccess Global-($2M)--(0.0x)-
M2Bio Sciences$80M$3M0.0x-0.0x-
Scorpius Holdings$6M($26M)1.9x-(0.5x)-
Vaxxinity-($56M)--(0.0x)-
Virpax Pharmaceuticals-($12M)--(0.0x)-
Lipella Pharmaceuticals$536K($5M)----
IO Biotech-($98M)----
Iterum Therapeutics-($22M)-28.4x(1.0x)(0.9x)

This data is available for Pro users. Sign up to see all Neovacs competitors and their valuation data.

Start Free Trial

Investments by Neovacs

Neovacs has invested in 2 companies to date.

Latest investment by Neovacs was on October 20th 2021. Neovacs invested in Signia Therapeutics in their $2M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Neovacs

Signia Therapeutics
Bio-Detection K9
Description
Signia Therapeutics is a clinical-stage biopharma company repurposing approved drugs for antiviral treatments against respiratory viruses including influenza, RSV, and coronaviruses. Headquartered in Paris, France, the firm uses AI to match drugs with viral targets, advancing candidates to Phase II trials. Signia Therapeutics partners with Sanofi for repurposing pipelines and focuses on rapid-response therapies for outbreaks. Its lead asset targets SARS-CoV-2 variants.
Bio-Detection K9 is a U.S.-based specialist in biological threat detection using trained canines and satellite imagery analysis. The company deploys dogs for rapid identification of pathogens in agriculture and human health settings, achieving over 95% accuracy in distinguishing diseases like foot-and-mouth in livestock and viral agents in humans. Its satellite service scans vast areas for crop anomalies via spectral variations, pinpointing GPS coordinates for ground verification. Headquartered in Florida, Bio-Detection K9 serves USDA and border security agencies.
HQ CountryFranceUnited States
HQ City
Lyon
Anniston, AL
Deal Date20 Oct 202127 Sep 2021
RoundSeries ASeed
Raised$2M$5M
InvestorsNeovacsNeovacs
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Neovacs investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Neovacs

When was Neovacs founded?Neovacs was founded in 1993.
Where is Neovacs headquartered?Neovacs is headquartered in France.
How many employees does Neovacs have?As of today, Neovacs has over 16 employees.
Who is the CEO of Neovacs?Neovacs' CEO is Hugo Brugiere.
Is Neovacs publicly listed?Yes, Neovacs is a public company listed on Euronext Paris.
What is the stock symbol of Neovacs?Neovacs trades under ALNEV ticker.
When did Neovacs go public?Neovacs went public in 2011.
Who are competitors of Neovacs?Neovacs main competitors include Novaccess Global, M2Bio Sciences, Scorpius Holdings, Vaxxinity, Virpax Pharmaceuticals, Lipella Pharmaceuticals, IO Biotech, Iterum Therapeutics, Lyra Therapeutics, Evofem Biosciences.
What is the current market cap of Neovacs?Neovacs' current market cap is $8K.
What is the current revenue of Neovacs?Neovacs' last fiscal year revenue is $355K.
What is the current EV/Revenue multiple of Neovacs?Current revenue multiple of Neovacs is 2.2x.
Is Neovacs profitable?No, Neovacs is not profitable.
How many companies Neovacs has acquired to date?Neovacs hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Neovacs has invested to date?As of November 2026, Neovacs has invested in 2 companies.
What was the last Neovacs investment?On 20th October 2021 Neovacs invested in Signia Therapeutics, participating in a $2M Series A round.

See public comps similar to Neovacs

Lists including Neovacs

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial